Completion of treatment · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: baclofen versus clonidine compared with other pharmacological detoxification treatment (very low certainty).
4 findings from 1 review
RR 1.06 [0.63, 1.8]
66 participants
Very low
RR 2.01 [1.69, 2.38]
361 participants
Low
RR 0.95 [0.65, 1.37]
72 participants
Very low
Show 1 more finding
Completion of treatment: clonidine versus clonidine plus amantadine, inpatient setting · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus clonidine plus amantadine,… compared with other pharmacological detoxification treatment (very low certainty).
1 finding from 1 review
RR 1.03 [0.86, 1.24]
69 participants
Very low
Completion of treatment: clonidine versus buprenorphine, inpatient setting · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus buprenorphine, inpatient… compared with other pharmacological detoxification treatment (very low certainty).
1 finding from 1 review
RR 1.04 [0.9, 1.2]
35 participants
Very low
Completion of treatment: methadone versus methadone plus gabapentin · management of opium withdrawal
Pharmacological detoxification treatment showed no clear difference in completion of treatment: methadone versus methadone plus gabapentin compared with other pharmacological detoxification treatment (low certainty).
1 finding from 1 review
Withdrawal symptoms · management of opium withdrawal
4 findings from 1 review
Show 1 more finding
no estimate extracted
34 participants
Very low
use of opiate during treatment ( · patients with opioid detoxification
Any Psychosocial plus any Pharmacological probably leads to lower use of opiate during the treatment objective compared with any Pharmachological alone compared to (moderate certainty).
1 finding from 1 review
Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Amount of cocaine use (mean weight of cocaine used or money spent on cocaine at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Continuous abstinence from cocaine (number of participants who had achieved and maintained abstinence for at least three weeks at the end of treatment) · patients with the treatment of cocaine dependence
Summary of findings table – disulfiram showed no clear difference in continuous abstinence from cocaine (number of participants who had… compared with placebo or no pharmacological treatment (low certainty).
1 finding from 1 review
Point abstinence (number of participants who were abstinent at the end of the treatment) · patients with the treatment of cocaine dependence
Summary of findings table – disulfiram may leads to higher point abstinence (number of participants who were abstinent at the… compared with placebo or no pharmacological treatment (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · patients with the treatment of cocaine dependence
Summary of findings table – disulfiram showed no clear difference in dropout for any reason (number of participants who did not complete… compared with placebo or no pharmacological treatment (low certainty).
1 finding from 1 review
Dropouts due to adverse events · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout due to adverse events (number of participants who did not… compared with placebo or no pharmacological treatment (very low certainty).
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Intervention not reported
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment: Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Dropout · patients with opioid detoxification
Any Psychosocial plus any Pharmacological probably leads to lower dropouts ‐ All studies objective compared with any Pharmachological alone compared to (moderate certainty).
1 finding from 1 review
Dropout ‐ Studies with low risk of bias · patients with opioid detoxification
Any Psychosocial plus any Pharmacological leads to lower dropouts ‐ Only studies with low risk of bias objeive compared with any Pharmachological alone compared to (high certainty).
1 finding from 1 review
Results at · patients with opioid detoxification
Any Psychosocial plus any Pharmacological probably leads to lower results at compared with any Pharmachological alone compared to (moderate certainty).
2 findings from 1 review
Compliance as clinical absences during the tratment objective · patients with opioid detoxification
Any Psychosocial plus any Pharmacological probably leads to lower compliance as clinical absences during the tratment objective compared with any Pharmachological alone compared to (moderate certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes any adverse events (number of participants who experienced at least… compared with placebo or no pharmacological treatment (very low certainty).
1 finding from 1 review